Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Cancer type

ALL

Acute lymphoblastic leukemia.

Must-know

  1. 1

    UKALL 2003: augmented therapy for MRD-high-risk ALL

    Vora et al. The Lancet Oncology. 2014.

    533 children and young people with MRD of 0.01% or higher at the end of induction were randomized. Five-year event-free survival was 89.6% with augmented post-remission therapy and 82.8% with standard therapy (odds ratio 0.61, 95% CI 0.39–0.98). The augmented regimen had more adverse events.

    PMID 24924991DOI

  2. 2

    MRD and outcome in pediatric and adult ALL

    Berry et al. JAMA Oncology. 2017.

    This meta-analysis pooled 39 publications and 13,637 patients. The event-free survival hazard ratio for MRD negativity was 0.23 (95% Bayesian credible interval 0.18–0.28) in children and 0.28 (0.24–0.33) in adults.

    PMID 28494052DOI

Listed when a study is a randomized or prospective interventional ctDNA or MRD trial, is cited in NCCN or ESMO guidance, or is a prospective validation cohort in a high-impact journal. Shorter lists mean fewer studies met that rule. No test is ranked.

Publications and presentations

Accruing studies for ALL

Regulatory timeline

  1. 2018-03-29

    FDA expands blinatumomab (Blincyto) approval to MRD-positive B-cell precursor ALL

    On March 29, 2018, FDA granted accelerated approval of blinatumomab for adults and children with B-cell precursor ALL in first or second complete remission with MRD ≥0.1%, based on the single-arm BLAST study. Supporting trial results are in Gökbuget et al., Blood 2018 (PMID 29358182).

  2. 2018-09-28

    FDA authorizes clonoSEQ, the first NGS-based MRD test for multiple myeloma and B-cell ALL

    On September 28, 2018, FDA granted De Novo authorization for Adaptive Biotechnologies' clonoSEQ assay to detect and monitor MRD in bone-marrow samples from patients with multiple myeloma or B-cell acute lymphoblastic leukemia, with the agency describing detection of remaining cancer cells at very low levels (down to about 1 in 1,000,000 cells).

ALL

6 records

  • Level 1myeloma/ALLpositive2018 · 2018-09-28

    FDA authorizes clonoSEQ, the first NGS-based MRD test for multiple myeloma and B-cell ALL

    U.S. Food and Drug Administration. FDA press announcement (De Novo DEN170080). clonoSEQ NGS, bone marrow

    On September 28, 2018, FDA granted De Novo authorization for Adaptive Biotechnologies' clonoSEQ assay to detect and monitor MRD in bone-marrow samples from patients with multiple myeloma or B-cell acute lymphoblastic leukemia, with the agency describing detection of remaining cancer cells at very low levels (down to about 1 in 1,000,000 cells).

    De Novo decision summary

  • Level 1ALLpositive2018 · 2018-03-29

    FDA expands blinatumomab (Blincyto) approval to MRD-positive B-cell precursor ALL

    U.S. Food and Drug Administration. FDA press announcement. MRD ≥10^-3 (0.1%) as the eligibility threshold in BLAST

    On March 29, 2018, FDA granted accelerated approval of blinatumomab for adults and children with B-cell precursor ALL in first or second complete remission with MRD ≥0.1%, based on the single-arm BLAST study. Supporting trial results are in Gökbuget et al., Blood 2018 (PMID 29358182).

  • Level 2ALLpositive2018

    Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia (BLAST)

    Gökbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, et al.. Blood. PMID 29358182. MRD ≥10^-3 at eligibility; complete MRD response after cycle 1 (primary endpoint) · n=116

    Open-label single-arm study: 116 adults with B-cell precursor ALL in hematologic CR with MRD ≥10^-3 received blinatumomab for up to 4 cycles. 88 of 113 evaluable patients (78%) achieved a complete MRD response after 1 cycle. In 110 Ph-negative patients, 18-month RFS was 54%; median OS 36.5 months. Complete MRD responders had longer RFS (23.6 vs 5.7 months, P=0.002) and OS (38.9 vs 12.5 months, P=0.002) than nonresponders. This trial supported the March 29, 2018 FDA approval. Single-arm (level 2); the approval itself is filed as regulatory level 1.

    Full text

  • Level 2ALLpositive2020

    Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults (D-ALBA / GIMEMA LAL2116)

    Foà R, Bassan R, Vitale A, Elia L, Piciocchi A, Puzzolo MC, et al.. N Engl J Med. PMID 33085860. Molecular MRD in Ph+ ALL

    Chemo-free induction/consolidation with dasatinib followed by blinatumomab in adults with newly diagnosed Ph-positive ALL, with molecular MRD as a central response measure. Single-arm (level 2). Long-term results: Foà et al., J Clin Oncol 2024 (PMID 38127722).

  • Level 1ALLpositive2024

    Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults (E1910)

    Litzow MR, Sun Z, Mattison RJ, Paietta EM, et al.. N Engl J Med. PMID 39047240. Flow-cytometry MRD; MRD-negative defined as <0.01% leukemic cells in bone marrow · n=224

    Phase 3 trial in adults 30-70 years with BCR::ABL1-negative BCP-ALL who had MRD-negative remission after induction/intensification. 224 MRD-negative patients were randomized 1:1 to 4 cycles of blinatumomab plus consolidation chemotherapy vs chemotherapy alone. At median follow-up 43 months, 3-year OS was 85% vs 68% (HR for death 0.41, 95% CI 0.23-0.73, P=0.002); 3-year RFS 80% vs 64% (HR 0.53, 95% CI 0.32-0.87). Level 1 (randomized, MRD-defined eligibility).

    Full text

  • Level 1ALLpositive2025

    Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children (COG AALL1731)

    Gupta S, Rau RE, Kairalla JA, Rabin KR, et al.. N Engl J Med. PMID 39651791. MRD used in COG risk assignment (standard-risk average or higher risk of relapse) · n=1440

    Phase 3 trial of children with newly diagnosed standard-risk B-cell ALL at average or higher risk of relapse, randomized to chemotherapy alone (n=722) or chemotherapy plus two nonsequential 28-day blinatumomab cycles (n=718). Interim analysis led to early termination of randomization. At median follow-up 2.5 years, estimated 3-year DFS was 96.0±1.2% vs 87.9±2.1% (P<0.001). Among average-risk: 97.5±1.3% vs 90.2±2.3%; among higher-risk: 94.1±2.5% vs 84.8±3.8%. Level 1 (randomized; MRD contributes to COG risk groups).

    Full text